Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant GP chemotherapy plus tislelizumab vs capecitabine in resected high‑risk intrahepatic cholangiocarcinoma
ChiCTR2500105630Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab, gemcitabine, cisplatin and capecitabine in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: 2-year disease-free survival rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
tislelizumabgemcitabinecisplatincapecitabine
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2500105630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105630.